Skip to content
Medical Health Aged Care

New Monash study represents major steps forward to reduce Australia’s unintended pregnancies

Monash University 2 mins read
  • Media:

The newly published ACCORd follow up study by Monash University’s SPHERE Centre of Research Excellence will help address Australia’s chronically low use of the most effective types of contraception, long acting reversible contraceptives (LARC), and high number of unintended pregnancies. 

Australian LARC use sits around 11 per cent, compared to countries like Sweden, other parts of Europe and the United Kingdom, which have over 30 per cent use.

In Australia, one in four women experience an unintended pregnancy, and a third of those end in abortion. It is higher amongst women aged 18-32 years and those living in non-urban areas. 

The ACCORd trial involved training GPs in contraceptive counselling and providing them with a rapid pathway to a LARC inserter.  Results were published in 2020 and demonstrated much higher rates of LARC uptake in women attending these GPs.

The follow up study, published this month in the American Journal of Obstetrics and Gynecology checked in with the women after three years.

Of the original ACCORd trial, 75 per cent of participants agreed to take part in the follow-up study. At three years, the continuation rate of long-acting reversible contraception was 66 per cent, significantly higher than for non-LARC methods at 55 per cent. 

Satisfaction with their method of contraception was higher among LARC users compared to oral contraceptive pill users. 

LARC use at three years was also significantly higher among women attending the Intervention GPs (41 per cent) compared to 28 per cent in women attending control GPs.  

Participants who consulted with the Intervention GPs experienced significantly fewer unintended pregnancies – 3.1 per cent compared to 6.3 per cent for participants who received regular advice– and also fewer abortions at 0.9 per cent compared to 3.6 per cent.

The Head of Monash University’s Department of General Practice and SPHERE Director, Professor Danielle Mazza, said the ACCORd project has far reaching implications for contraception in Australia.

“The results demonstrate that GP training in contraceptive counselling and the opportunity to rapidly refer women for LARC insertion if GPs don’t provide that service themselves has a long-term sustained impact on the continuation rate of LARC methods, and reduces the numbers  of unintended pregnancies and abortion,” Professor Mazza said. 

 

“The ACCORd trial and follow up study has informed the Federal Government’s recent announcement of additional LARC training centres of excellence, training opportunities and financial incentives for GPs and other primary care practitioners, and subsidies that significantly lower the cost for women to access these methods.” 

 

The ACCORd project, conducted by SPHERE, comprised two major studies:

  1. ACCORd Trial: A trial to train GPs in contraceptive counselling and provide rapid insertion of LARC devices – involving 57 GPs and 740 women. The results were published in 2020.
  2. ACCORd Follow-up Study: A three-year follow-up with women participants to assess their ongoing use of LARCs involving 75 per cent of the original group of women.

Read the full paper in American Journal of Obstetrics and Gynecology: “Increasing the uptake of long-acting reversible contraception through family practice: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized controlled trial 3-year follow-up”

 

DOI: https://doi.org/10.1136/bmjopen-2019-035895

 

 

For media enquiries please contact:

Monash University

Helena Powell – Media Advisor (medical)
E: helena.powell@monash.edu 

T: +61 (0) 474 444 171

 

For more Monash media stories, visit our news and events site  


For general media enquiries please contact:
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840

More from this category

  • Medical Health Aged Care
  • 24/04/2025
  • 15:11
Galderma Group AG

Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance

Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland–BUSINESS WIRE– Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales…

  • Contains:
  • Medical Health Aged Care
  • 24/04/2025
  • 14:32
Dementia Australia

Memory Walk & Jog Templestowe just weeks away!

The 2025 Templestowe Memory Walk & Jog is just a few short weeks away, with the event taking place on Sunday 11 May at Westerfolds Park, Templestowe. Following overwhelming support from the Templestowe community, we are bringing Memory Walk & Jog to Westerfolds Park, Templestowe in 2025. Memory Walk & Jog Templestowe will help advance the work of Dementia Australia, which delivers invaluable support, education and resources for people living with dementia, their families and carers. Memory Walk & Jog is about being part of the community and feeling supported. We are in this together, which is why participants can…

  • Contains:
  • Medical Health Aged Care
  • 24/04/2025
  • 13:05
Dementia Australia

Memory Walk & Jog South East Melbourne just weeks away!

The 2025 South East Melbourne Memory Walk & Jog is just a few short weeks away, with the event taking place on Saturday 10 May at Peter Scullin Reserve, Mordialloc. Heading to South East Melbourne for the first time, Memory Walk & Jog will help advance the work of Dementia Australia, which delivers invaluable support, education and resources for people living with dementia, their families and carers. Memory Walk & Jog is about being part of the community and feeling supported. We are in this together, which is why participants can walk, jog or run and select from either 2.5km,…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.